anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pre-implantation genetic testing (PGT) is a crucial process for selecting embryos created through assisted reproductive technology (ART). Couples with chromosomal rearrangements, infertility, recurrent miscarriages, advanced maternal age, known single-gene disorders, a family history of genetic conditions, previously affected pregnancies, poor embryo quality, or congenital anomalies may be candidates for PGT. Preimplantation genetic testing for aneuploidies (PGT-A) enables the selection and transfer of euploid embryos, significantly enhancing implantation rates in assisted reproduction. Fluorescence in situ hybridization (FISH) is the preferred method for analyzing biopsied cells to identify these abnormalities. While FISH is a well-established method for identifying sperm aneuploidy, NGS offers a more comprehensive assessment of genetic material, potentially enhancing our understanding of male infertility. Chromosomal abnormalities, arising during meiosis, can lead to aneuploid sperm, which may hinder embryo implantation and increase miscarriage rates. This review provides a comparative analysis of fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) in sperm evaluations, focusing on their implications for preimplantation genetic testing. This analysis explores the strengths and limitations of FISH and NGS, aiming to elucidate their roles in improving ART outcomes and reducing the risk of genetic disorders in offspring. Ultimately, the findings will inform best practices in sperm evaluations and preimplantation genetic testing strategies.
The invention relates to overcoming anti-cancer therapy resistance in melanoma by regulation of the expression of tyrosinase related protein 2 (TYRP2).  Treatment of melanoma with anti-cancer therapy may be negatively impacted by anti-cancer resistance of melanoma cells. Altering expression of TYRP2 in melanoma cells can enhance efficacy of anti-cancer therapies, such as chemotherapy and radiotherapy. The use of a reducer, ase well as methods for treatment of melanoma are disclosed. Further, methods for diagnosis of anti-cancer therapy resistance, and methods for evaluating candidate anti-cancer therapies for melanoma. Down-regulation of TYRP2 expression or activity can be accomplished using a genetic therapy such as antisense therapy, or by using small molecules which regulate TYRP2.
Primary ciliary dyskinesia (PCD) is a genetic disorder characterized by ciliary structural abnormalities and dysfunction, leading to chronic rhinosinusitis, otitis media with effusion, bronchiectasis, and infertility. Approximately half of Japanese PCD cases are attributed to variants in the dynein regulatory complex subunit 1 (DRC1) gene, predominantly featuring homogeneous deletions of exons 1-4 spanning 27,748 base pairs on chromosome 2. Here, we report 10 new PCD cases (9 families) in addition to 29 previously reported cases (24 families) caused by DRC1 variants. Among these 39 cases, biallelic DRC1 exon 1-4 deletions were detected in 38 (97.4%). These DRC1 deletions exhibited an identical breakpoint in all PCD cases in the Japanese and Korean populations, strongly suggesting a founder effect. In this study, we performed haplotype analysis, using a whole-exome sequencing dataset of 18 Japanese PCD patients harboring large biallelic DRC1 deletions. We estimated that the founder allele likely emerged 115.1 generations ago (95% confidence interval: 33.7-205.1), suggesting an origin of approximately 3050 years ago, coinciding with the transition from the Jomon period to the early Yayoi period in Japan. Considering the formation of the modern Japanese population, the founder with the DRC1 exon 1-4 deletion likely lived on the Korean peninsula, with the allele later transmitted to Japan through migration. This study provides insights into the origin of the DRC1 copy number variant, the most frequent PCD variant in the Japanese and Korean populations, highlighting the importance of understanding population-specific genetic variations in the context of human migration and disease prevalence.
Individuals suffering from long-COVID can present with "brain fog", which is characterized by a range of cognitive impairments, such as confusion, short-term memory loss, and difficulty concentrating. To date, several potential interventions for brain fog have been considered. Notably, no systematic review has comprehensively discussed the impact of each intervention type on brain fog symptoms. We included studies on adult (aged > 18 years) individuals with proven long- COVID brain-fog symptoms from PubMed, MEDLINE, Central, Scopus, and Embase. A search limit was set for articles published between 01/2020 and 31/12/2023. We excluded studies lacking an objective assessment of brain fog symptoms and patients with preexisting neurological diseases that affected cognition before COVID-19 infection. This review provided relevant information from 17 studies. The rehabilitation studies utilized diverse approaches, leading to a range of outcomes in terms of the effectiveness of the interventions. Six studies described noninvasive brain stimulation, and all showed improvement in cognitive ability. Three studies described hyperbaric oxygen therapy, all of which showed improvements in cognitive assessment tests and brain perfusion. Two studies showed that the use of Palmitoylethanolamide and Luteolin (PEA-LUT) improved cognitive impairment. Noninvasive brain stimulation and hyperbaric oxygen therapy showed promising results in the treatment of brain fog symptoms caused by long-COVID, with improved perfusion and cortical excitability. Furthermore, both rehabilitation strategies and PEA-LUT administration have been associated with improvements in symptoms of brain fog. Future studies should explore combinations of interventions and include longer follow-up periods to assess the long-term effects of these treatments.
There are provided systems and methods for shared account enrollment and biometric activity monitoring for value apportionment. A shared account may be generated to track biometric activity for multiple users and provide a shared value that may be apportioned among the users based on the biometric activity. The account may be set with rewards or goals based on the biometric activity. A service provider may provide a biometric tracking platform having a portal where each user may enter an account code or identifier for the account, and link the account to a biometric tracking device and/or online service that interacts with the biometric tracking device to determine activity data for each user. Based on the activity data, each user may receive portions of the shared value at particular time interfaces for accomplishing the goals. The activity may be tracked in real-time and output through comparison interfaces.
PURPOSE:To prevent a soft capsule from mutually sticking even at high temperature and humidities, enhance sliding properties in compounding and packaging operations and improve operating efficiency by blending dietary fiber in a film of the soft capsule. CONSTITUTION:A capsule is obtained by blending >=0.5wt.%, preferably 1-30wt.% dietary fiber or its derivative or its processed substance in a film of the soft capsule. The dietary fiber refers to hardly digestible ingredients which are not digested with human digestive enzymes in foods and agar, carrageenan, alginic acid, chitin, pectin, xanthan gum, lignin, etc., are cited. Calcium alginate, chitosan, hydroxypropyl starch, etc., are cited as their derivatives. A dietary fiber-containing processed food obtained by processing a dietary fiber-containing food or other raw materials by various methods, e.g. a processed food containing a homogeneous substance of cellulose, regenerated from an aqueous solution of an alkali metallic hydroxide and having crystal type of cellulose II and edible polysaccharides in an amount of >=10% as a continuous substance is cited as the aforementioned processed substance.
Pylephlebitis is defined as suppurative thrombosis of the portal vein as a complication of abdominal infections. In pediatrics, the most frequent etiology is appendicitis, generally of late diagnosis, presenting as sepsis, with a high mortality rate. Imaging methods are necessary for diagnosis; the most common are the Doppler ultrasound and computed tomography angiography. Treatment is based on surgery, antibiotic therapy, and anticoagulation. The indication for the latter is controversial, but it may improve prognosis and decrease morbidity and mortality. Here we describe a clinical case of pylephlebitis secondary to Escherichia coli sepsis, which started as acute appendicitis in a pediatric patient who progressed to cavernomatous transformation of the portal vein. It is important to know the management of this disease because, once the initial symptoms are overcome, it will require close follow-up due to a potential progression to liver failure.
The invention discloses a hyaluronic acid targeted polydopamine coated phase-change liquid fluorocarbon nano ultrasonic contrast agent. The particle size of the hyaluronic acid targeting polydopamine coated phase change type liquid fluorocarbon nano ultrasonic contrast agent prepared by a film-emulsification method and an oxidation polymerization method is about 248.08nm, and in vitro experiments show that the hyaluronic acid targeting polydopamine coated phase change type liquid fluorocarbon nano ultrasonic contrast agent has good stability. Cytological experiments show that the biocompatibility of the hyaluronic acid targeting polydopamine coated phase-change liquid fluorocarbon nano ultrasonic contrast agent is good. In vivo experiments show that the hyaluronic acid targeted polydopamine coated phase-change liquid fluorocarbon nano ultrasonic contrast agent has a good ultrasonic imaging effect. Meanwhile, the combined application of the photothermal therapy and the chemotherapy shows good tumor inhibition effect. The hyaluronic acid targeted polydopamine coated phase-change liquid fluorocarbon nano ultrasonic contrast agent prepared by the invention has the advantages of simple and convenient process, good biocompatibility of the used materials and wide application prospect.
Subjects in the intervention group will be offered a free POC-cHbA1c test to screen for hyperglycemia. The test will be performed on-site (i.e. during the same clinic visit of recruitment). Test results will be available within 10 minutes and the subject will be immediately informed of his/her DM risk, and for those with HbA1c≥5.6%, a confirmatory OGTT will be arranged on-site, scheduled within 2-4 weeks and ideally at the same clinic.
This invention relates to the compositions and methods of use of macromolecular nitroxide as a nano anti-radical therapy (NanoART) to compliment current chemotherapy, radiotherapy, immunotherapy, hormonal therapy, biological therapy and surgery in the treatment of cancer. NanoART is unique in that it inhibits all three key steps in carcinogenesis. NanoART inhibits proliferation, progression and metastasis of cancer processes through the free radical based reactive oxygen species pathway. This is a novel comprehensive therapy which has not been addressed by current standard cancer therapies with a single therapeutic agent. NanoART may also exert its anti-cancer activities throughout the body regardless of the location of its administration, and this is a revolutionary new paradigm in medical treatment. As a treatment of carcinogenesis, NanoART has the potential to decrease morbidity, decrease mortality and improve the cure of cancer.
In this group decongestants and anesthesia (oxymetazoline and lidocaine) sprays will be used. Decongestant (Oxymetazoline 0.05%) will be give as described above. After two minutes, lidocaine 15% (Nummit) spray will be given as described above. Procedure will be done after five minutes of decongestant.
A system and method for providing access to secure information. The method includes using a computing device to detect a connection between the computing device and an electronic key. The electronic key stores an encrypted unique electronic identifier (UEID). The method also includes using the computing device to authenticate a provider identifier (ID). If the provider ID is authentic and the electronic key is connected to the computing device the UEID is accessed. A request to access secure information is transmitted by the computing device to a secure storage device. Access to the secure information is granted based on the authenticated provider ID and a set of access preferences associated with the UEID. The computing device receives the requested secure information if the request is granted.
Elderly, Gender, Race: Because of a large number of immeasurable plasma concentrations (< 1ng/mL), any potential pharmacokinetic differences between Special Populations could not be assessed.

Pediatric: Studies to evaluate bexarotene pharmacokinetics in the pediatric population have not been conducted (see PRECAUTIONS, Pediatric Use).

Renal Insufficiency: No formal studies have been conducted with Bexarotene gel in patients with renal insufficiency. Urinary elimination of bexarotene and its known metabolites is a minor excretory pathway (<1% of an orally administered dose), but because renal insufficiency can result in significant protein binding changes, pharmacokinetics may be altered in patients with renal insufficiency (see PRECAUTIONS, Renal Insufficiency).

Hepatic Insufficiency: No specific studies have been conducted with Bexarotene gel in patients with hepatic insufficiency. Because less than 1% of the dose of oral bexarotene is excreted in the urine unchanged and there is in vitro evidence of extensive hepatic contribution to bexarotene elimination, hepatic impairment would be expected to lead to greatly decreased clearance (see PRECAUTIONS, Hepatic Insufficiency).
BACKGROUND: Functional/dissociative seizures (FDS), also known as psychogenic non-epileptic seizures (PNES), are sudden, transient, and involuntary events that include motor, sensory, cognitive or autonomic function alterations. In this work we analyzed the psychopathological characteristics of a subgroup of women who suffer from FDS with the aim to analyze the role of psychological trauma, with special emphasis on trauma due to sexual abuse (SA).
METHODS: Forty-five women diagnosed with FDS were included in the study (age range 18 to 64 years, mean = 34.7, standard deviation (SD) = 13.1). Clinical and psychopathological characteristics were reviewed. All patients have completed the clinical interviews, the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID II) and the Global Assessment of Functioning (GAF) according to a special protocol for mental health assessment. Also, the history of sexual abuse trauma, the history of other non-sexual traumas and absence of history of trauma were reviewed.
RESULTS: Eighty percent of the cases reported a history of trauma, and 40% reported a history of SA. Patients with a history of SA presented a significantly lower average age of seizure onset than patients with a history of other non-sexual traumas (p = 0.021). Significant associations were found between SA and post-traumatic stress disorder (PTSD) (p = 0.031), and SA and history of suicide attempts (p = 0.037).
CONCLUSIONS: SA carries serious implications for the mental health of women suffering from FDS. Mental health professionals must consider the history of this type of trauma to provide the necessary care for this patient population.
PURPOSE: The purpose of the study was to evaluate the quantitative relationship between Oxygen Desaturation Index (ODI) and sleep structure of obstructive sleep apnea (OSA) and cardiac remodeling.
METHODS: In this study, patients were enrolled from January 2015 to October 2022, and were divided into 3 groups according to AHI: patients with AHI < 15, patients with 15 ≤ AHI < 30, and 260 patients with AHI ≥ 30. Stratified linear regression was used to analyze independent risk factors for cardiac remodeling in OSA.
RESULTS: A total of 479 patients were enrolled. We found that compared with AHI < 15 group (n = 120), the group with AHI > 30 (n = 260) had increased left atrial anteroposterior diameter, left ventricular end-diastolic internal diameter, left ventricular posterior wall thickness, right ventricular anteroposterior diameter, and interventricular septal thickness (P < 0.05). The group with 15 ≤ AHI ≤ 30 (n = 99) had increased left atrial anteroposterior diameter (P < 0.05). Multivariate linear regression revealed that N2 sleep was an independent risk factor for left ventricular posterior wall thickness, with positive correlation (p < 0.05). N3 sleep was an independent risk factor for transverse right atrial diameter and right ventricular anteroposterior diameter, with negative correlation (P < 0.05). ODI was an independent risk factor for interventricular septal thickness, with positive correlation (P < 0.05). The arousal index was an independent risk factor for increased left atrial anteroposterior diameter, with positive correlation (P < 0.05).
CONCLUSIONS: Increased ODI is an independent risk factor for interventricular septal thickness, while decreased slow wave sleep is an independent risk factor for right heart remodeling in OSA.
Expression of ZAP-70 in a subset of patients with chronic lymphocytic leukemia (CLL) positively correlates with the absence of immunoglobulin heavy-chain gene (IGHV) mutations and is indicative of a more active disease and shorter treatment-free survival. We recently demonstrated that ZAP-70 regulates the constitutive expression of CCL3 and CCL4, activation of AKT, and expression of MYC in the absence of an overt B-cell receptor (BCR) signal, bona fide functions of BCR activation. We, here, provide evidence that these features relate to the presence of a constitutive tonic BCR signal, exclusively found in IGHV-unmutated CLL and dependent on the ZAP-70-mediated activation of AKT and its downstream target GSK-3β. These findings are associated with increased steady-state activation of CD19 and SRC. Notably this tonic BCR signal is not present in IGHV-mutated CLL cells, discordantly expressing ZAP-70. Results of quantitative mass spectrometry and phosphoprotein analyses indicate that this ZAP-70-dependent, tonic BCR signal regulates CLL cell migration through phosphorylation of LCP1 on serine-5. Indeed, we show that CCL19- and CCL21-induced chemotaxis is regulated by and dependent on the expression of ZAP-70 through its function to enhance CCR7 signaling to LCP1. Thus, our data demonstrate that ZAP-70 converges a tonic BCR signal, exclusively present in IGHV-unmutated CLL and CCR7-mediated chemotaxis.
Minnesota Hmong are a unique population of individuals of South East Asian descent who have been noted to have a higher prevalence of gout and gout related comorbidities compared to non-Hmong. Elevated levels of uric acid are thought to be at the root cause of gout. Elevated levels of serum uric acid can result from either overproduction and or under-excretion. Xanthine oxidase plays a key role in the breakdown of purines to form uric acid. Transporters in the kidney also play a key role in excretion and/or re-absorption of uric acid. The objective of this study is to explore whether genetic variations in renal transporters may influence the disposition of serum uric acid in response to a drug (allopurinol) as well as the disposition of its active metabolite (oxipurinol) which may also be a substrate for these same transporters responsible for uric acid disposition. Genetic variations unique to the Hmong population may explain their increased prevalence in gout and or perceived lack of responsiveness to the drug (allopurinol) used to treat the condition.
Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
The invention relates to a single dose eye drop containing polyvinyl alcohol. The eye drop appliesthe polyvinyl alcohol as the main material, and isotonizing agent, tackifier and other function assistants are used for improving the osmotic pressure, viscosity and stability of the eye drop. The average molecular weight of the polyvinyl alcohol used in the eye drop is 50000 Da-140000 Da. The polyvinyl alcohol has medium viscosity, can guarantee the contact time between the medicine and eye tissues, and enhance the therapeutic effects. The eye drop contains no anti-corrosive agent. The prepared single dose eye drop can effectively reduce the stimulation and damage of the medicinal liquor to the eye tissues, avoid the negative reaction brought by a bacteriostatic agent, and enhance the medical serving correctness.
FIELD: medicine. SUBSTANCE: invention relates to biocompatibility of oxygen transfers for administration to patients as an addition or partial substitution of whole blood. Hemoglobin conjugates that can be used as oxygen transfers based on hemoglobin are prepared using providing hemoglobin reaction with polysaccharides with ring opened in oxidation, such as hydroxyethylstarch or dextran and storage the prepared conjugate under conditions that allow to its after conjugation to be transformed into product with lower molecular mass. Then conjugate is subjected for reductive stabilization to form secondary amino-bonds between hemoglobin and polysaccharide and to make the hemoglobin-base composition as an oxygen transfer. Method provides preparing new conjugate polysaccharide-hemoglobin. EFFECT: improved preparing method, valuable medicinal properties of conjugates. 45 cl, 12 dwg, 11 ex
All subjects in this arm (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at approximately 8 am followed by 1000 mg acetaminophen at approximately 10 am during one crossover period (see "Crossover period: Aspirin first" intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see "Crossover Period: Aspirin last" intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender.